[go: up one dir, main page]

PE20040706A1 - Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca - Google Patents

Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca

Info

Publication number
PE20040706A1
PE20040706A1 PE2003000735A PE2003000735A PE20040706A1 PE 20040706 A1 PE20040706 A1 PE 20040706A1 PE 2003000735 A PE2003000735 A PE 2003000735A PE 2003000735 A PE2003000735 A PE 2003000735A PE 20040706 A1 PE20040706 A1 PE 20040706A1
Authority
PE
Peru
Prior art keywords
prevention
pharmaceutically acceptable
heart failure
acceptable salts
body weight
Prior art date
Application number
PE2003000735A
Other languages
English (en)
Inventor
Brian Guth
Randolph Seidler
Juergen Daemmgen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040706(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20040706A1 publication Critical patent/PE20040706A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE CILOBRADINA Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE CUYO INTERVALO DE DOSIS ES: 0,05 A 5 mg/Kg DE PESO CORPORAL; 0,1 A 2,5 mg/Kg DE PESO CORPORAL; 0,1 A 1 mg/Kg DE PESO CORPORAL; 0,1 A 0,75 mg/Kg DE PESO CORPORAL. DICHOS COMPUESTOS PERMITEN EL BLOQUEO COMPLETO DEL CANAL DE IONES CARDIACOS, UTILES EN EL TRATAMIENTO O PREVENCION DE INSUFICIENCIA CARDIACA DE CUALQUIER ETIOLOGIA
PE2003000735A 2002-07-25 2003-07-24 Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca PE20040706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016602A EP1362590B1 (en) 2002-07-25 2002-07-25 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Publications (1)

Publication Number Publication Date
PE20040706A1 true PE20040706A1 (es) 2004-12-06

Family

ID=29265956

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000735A PE20040706A1 (es) 2002-07-25 2003-07-24 Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca

Country Status (29)

Country Link
US (1) US20130317008A1 (es)
EP (2) EP1362590B1 (es)
JP (3) JP2005533853A (es)
KR (1) KR20050074432A (es)
CN (1) CN100502874C (es)
AR (1) AR040690A1 (es)
AT (2) ATE257384T1 (es)
AU (1) AU2003254554B8 (es)
BR (1) BR0312852A (es)
CA (1) CA2493208C (es)
CO (1) CO5700723A2 (es)
CY (1) CY1112173T1 (es)
DE (1) DE60200160T2 (es)
DK (2) DK1362590T3 (es)
ES (2) ES2211846T3 (es)
HR (1) HRP20050075B1 (es)
MX (1) MXPA05000617A (es)
MY (1) MY128529A (es)
NZ (1) NZ538424A (es)
PE (1) PE20040706A1 (es)
PL (1) PL214716B1 (es)
PT (2) PT1362590E (es)
SA (1) SA03240350B1 (es)
SI (2) SI1362590T1 (es)
TR (1) TR200400127T4 (es)
TW (1) TWI319321B (es)
UY (1) UY27910A1 (es)
WO (1) WO2004011006A1 (es)
ZA (1) ZA200500084B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
PT1362590E (pt) * 2002-07-25 2004-05-31 Boehringer Ingelheim Pharma Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca
US20090247572A1 (en) * 2005-08-23 2009-10-01 Koichi Wada Agent for treating atrial fibrillation
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2927538B1 (fr) 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
BR112014003061A2 (pt) * 2011-08-12 2017-02-21 Boehringer Ingelheim Vetmedica Gmbh composição farmacêutica com sabor mascarado
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) * 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
JP4240173B2 (ja) * 1998-06-03 2009-03-18 日産化学工業株式会社 インダン誘導体
PT1186601E (pt) * 1999-06-03 2004-06-30 Yamanouchi Pharma Co Ltd Novos derivados de isoquinolina ou seus sais
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
PT1362590E (pt) * 2002-07-25 2004-05-31 Boehringer Ingelheim Pharma Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca

Also Published As

Publication number Publication date
JP2009256379A (ja) 2009-11-05
CN100502874C (zh) 2009-06-24
DK1362590T3 (da) 2004-03-29
CY1112173T1 (el) 2015-12-09
TR200400127T4 (tr) 2004-02-23
AU2003254554A1 (en) 2004-02-16
PT1534296E (pt) 2011-08-18
MXPA05000617A (es) 2005-08-19
ZA200500084B (en) 2005-10-26
BR0312852A (pt) 2005-04-19
SI1362590T1 (en) 2004-04-30
PL372993A1 (en) 2005-08-08
AR040690A1 (es) 2005-04-13
ES2367109T3 (es) 2011-10-28
DK1534296T3 (da) 2011-08-15
EP1362590A1 (en) 2003-11-19
US20130317008A1 (en) 2013-11-28
EP1362590A8 (en) 2004-02-25
MY128529A (en) 2007-02-28
EP1534296B1 (en) 2011-05-25
JP2013166781A (ja) 2013-08-29
HRP20050075A2 (en) 2005-12-31
TW200412974A (en) 2004-08-01
JP2005533853A (ja) 2005-11-10
TWI319321B (en) 2010-01-11
PL214716B1 (pl) 2013-09-30
SA03240350B1 (ar) 2007-10-29
AU2003254554B2 (en) 2009-01-29
DE60200160T2 (de) 2004-11-04
HRP20050075B1 (hr) 2013-12-20
NZ538424A (en) 2006-10-27
ES2211846T3 (es) 2004-07-16
DE60200160D1 (de) 2004-02-12
KR20050074432A (ko) 2005-07-18
CO5700723A2 (es) 2006-11-30
EP1362590B1 (en) 2004-01-07
EP1534296A1 (en) 2005-06-01
ATE510543T1 (de) 2011-06-15
SI1534296T1 (sl) 2011-09-30
CA2493208A1 (en) 2004-02-05
UY27910A1 (es) 2004-02-27
CN1671392A (zh) 2005-09-21
WO2004011006A1 (en) 2004-02-05
PT1362590E (pt) 2004-05-31
CA2493208C (en) 2011-11-01
AU2003254554B8 (en) 2009-02-26
ATE257384T1 (de) 2004-01-15

Similar Documents

Publication Publication Date Title
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
CL2019003924A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
PA8591701A1 (es) Derivados de pirrolopirimidina
BRPI0816317A2 (pt) Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
NO20055880L (no) Memantin orale doseringsformer
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
PE20040706A1 (es) Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca
MX2023005462A (es) Compuestos macrociclicos y metodos para usarlos.
ECSP044986A (es) Composicion farmaceutica que comprende lumiracoxib
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
AR062779A1 (es) Tratamiento de la esclerosis multiple (em)
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina

Legal Events

Date Code Title Description
FC Refusal